AbbVie Reports Advancement of ABBV-383 to P-III Study for the Treatment of Multiple Myeloma
Shots:
- AbbVie has reported the first patient treatment with ABBV-383, being evaluated under the P-III (CERVINO) clinical trial for multiple myeloma
- The P-III (CERVINO) trial investigates ABBV-383 (60mg, IV, Q4W) vs SAT (carfilzomib + dexamethasone, elotuzumab + pomalidomide + dexamethasone, or selinexor + bortezomib + dexamethasone) to treat adults (n=380, ≥18yrs.) with r/r MM & ECOG performance status ≤2 who were administered with at least 2 previous lines of therapy such as a PI, an IMiD & an anti-CD38 mAb
- ABBV-383 is a BCMA x CD3 bispecific T-cell engager, comprising of a high-avidity BCMA-binding domain, a low-affinity CD3-binding domain that reduces cytokine release, and a silenced Fc tail to increase the half-life
Ref: Abbvie | Image: Abbvie
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
